endpoint Updates IRT Platform
San Francisco, CA – endpoint Clinical, a leading global interactive response technology (IRT) company, has announced a significant enhancement to its proprietary PULSE platform, reshaping the way IRT is applied to clinical trials.
San Francisco, CA –
“Since the initiation of endpoint in 2009, we have been continuously improving IRT through our organic growth model. The result is the industry’s most integrated and powerful combination of patient and clinical supply management,” said
endpoint has recently combined the cutting-edge features of its industry-leading configurable IRT platform, PULSE, with its revolutionary global inventory management tool, DRIVE, into a single, unified and seamless solution. This concept was developed with clinical supply experts across the industry and is packed with innovations. It extends IRT accessibility and affordability to clients’ entire clinical development portfolio, including investigator initiated trials (IIT) and early-phase, late-phase and compassionate use studies.
The IRT industry continues to operate at the protocol-level, despite the true industry need. The PULSE-DRIVE fusion shifts that paradigm to look across protocols, which provides access to novel functionality supporting operations and regulatory needs such as supply pooling, robust temperature-excursion management, and therapeutic- and compound-level reporting. By centralizing cross-protocol data, this solution seamlessly integrates with advanced simulation and optimization solutions to provide accurate upfront and ongoing forecasting for supply planning and operations in the field using actual IRT data.
“One of the key factors to the successful evolution of endpoint’s products is our leadership’s laser-like focus on the IRT space and how it should be transformed,” said
Read more about endpoint’s solutions at
About endpoint
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025